TOVX (Theriva Biologics) Beta: 1.3985 (As of Jun. 25, 2026)


TOVX Theriva Biologics Inc TOVX
28 GF Score
Price $0.24
! 3 Warning Signs
View Full Analysis

What is Theriva Biologics Beta?

Theriva Biologics TOVX 28 Beta is 1.3985 as of Jun. 25, 2026. GuruFocus rates TOVX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Theriva Biologics's Beta is 1.3985.


Theriva Biologics  (AMEX:TOVX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Theriva Biologics Beta Related Terms


Theriva Biologics Beta Historical Data

* Premium members only.

The historical data trend for Theriva Biologics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theriva Biologics Beta Chart

Theriva Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.34 1.00 1.04 1.16 1.02

Theriva Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 0.78 1.02 1.02 -0.21

TOVX vs CALC, PHIO, PHGE: Beta Comparison

For the Biotechnology subindustry, Theriva Biologics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Beta distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Beta falls into.


TOVX
28GF Score
Theriva Biologics Inc TOVX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theriva Biologics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.3985 mean?
Theriva Biologics (TOVX) has a Beta of 1.3985 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Theriva Biologics and its competitors.
Is Theriva Biologics' Beta too high?
Theriva Biologics' current Beta is 1.3985. Overall, Theriva Biologics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' Beta compare to CALC and PHIO?
Theriva Biologics' Beta of 1.3985 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Theriva Biologics and its competitors. Theriva Biologics's current Beta is 1.3985. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (TOVX) has a current Beta of 1.3985. The current Beta is 1.3985. Theriva Biologics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Theriva Biologics (TOVX), the current Beta is 1.3985 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Theriva Biologics Business Description

Address 9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
28GF Score

Get the complete analysis for TOVX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price